COX8A (Cytochrome c Oxidase Subunit 8A) is a nuclear-encoded mitochondrial protein that serves as a structural subunit of cytochrome c oxidase (Complex IV) of the electron transport chain. As one of the smallest subunits of Complex IV, COX8A plays a critical role in the assembly, stability, and function of this essential enzyme. In neurons, where energy demands are exceptionally high, COX8A supports oxidative phosphorylation and ATP production. COX8A dysfunction is implicated in neurodegenerative diseases including Alzheimer's disease and Parkinson's disease, where mitochondrial deficits contribute to neuronal vulnerability [1].
| COX8A — Cytochrome c Oxidase Subunit 8A | |
|---|---|
| Gene Symbol | COX8A |
| Full Name | Cytochrome c Oxidase Subunit 8A |
| Chromosome | 11q13.1 |
| NCBI Gene ID | [9419](https://www.ncbi.nlm.nih.gov/gene/9419) |
| OMIM | [603774](https://www.omim.org/entry/603774) |
| Ensembl ID | [ENSG00000160789](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000160789) |
| UniProt ID | [P10176](https://www.uniprot.org/uniprot/P10176) |
| Protein Length | 69 amino acids |
| Molecular Weight | ~7.8 kDa |
| Associated Diseases | AD, PD, Mitochondrial Disorders |
The COX8A gene is located on chromosome 11q13.1 and spans approximately 1.5 kb. It consists of three exons and encodes a 69-amino acid protein. As a nuclear-encoded gene, COX8A is transcribed in the nucleus, translated in the cytoplasm, and imported into mitochondria via the TOM/TIM translocase system [2].
Despite its small size, COX8A contains essential structural elements:
The protein lacks a cleavable targeting peptide in its mature form but contains hydrophobic transmembrane domains that anchor it within the inner membrane.
Cytochrome c oxidase (Complex IV) is the terminal enzyme of the mitochondrial electron transport chain, catalyzing the transfer of electrons from cytochrome c to molecular oxygen, coupled with proton pumping across the inner mitochondrial membrane [3].
Complex IV contains 13 subunits in mammals:
Catalytic subunits: COX1 and COX2 contain the heme a and heme a3 prosthetic groups and the Cu_A and Cu_B copper centers that mediate electron transfer
Core subunits: COX3 is also encoded by mtDNA and forms part of the catalytic core
Nuclear-encoded subunits: COX4, COX5A, COX5B, COX6A, COX6B, COX6C, COX7A2, COX7B, COX7C, COX8A
COX8A is the smallest nuclear-encoded subunit at just 69 amino acids. Despite its small size, it plays essential structural roles:
Complex IV receives electrons from cytochrome c and transfers them to molecular oxygen, reducing it to water. This reaction is coupled to the pumping of protons from the mitochondrial matrix to the intermembrane space, creating the electrochemical gradient that drives ATP synthase:
Cyt c (Fe²⁺) → Cu_A → COX1 heme a → COX1 heme a3-Cu_B → O₂ → H₂O
↑
Proton pumping (4 H⁺/e⁻)
In neurons, this process is critical for:
COX8A exhibits tissue-specific expression:
In the brain, COX8A is expressed in:
In the brain, COX8A expression is neuron-specific and correlates with mitochondrial density. Inhibitory neurons typically show higher COX activity than excitatory neurons due to their greater reliance on oxidative metabolism [4].
COX8A dysfunction is implicated in Alzheimer's disease (AD) through several mechanisms:
The 2025 study by Wang et al. demonstrates that amyloid-beta (Aβ) accumulation directly impairs cytochrome c oxidase function in Alzheimer's disease patient-derived cerebral organoids [5]. This mitochondrial dysfunction precedes overt neuronal loss and correlates with amyloid burden:
Tau pathology also affects mitochondrial function in AD [6]:
COX8A deficiency contributes to AD through metabolic disruption [7]:
COX8A and Complex IV deficits are central to Parkinson's disease pathogenesis:
PD is classically associated with Complex I deficiency in the substantia nigra. However, this also affects downstream Complexes [8]:
Alpha-synuclein (αSyn) pathology directly impacts mitochondria [9]:
Both AD and PD share common mitochondrial mechanisms:
Neuronal calcium dysregulation impacts mitochondrial function:
COX8A mutations cause autosomal recessive mitochondrial complex IV deficiency [10]:
Clinical features:
Biochemical findings:
Leigh Syndrome: The most common presentation of COX deficiency, characterized by:
COX8A deficiency can also cause cardiomyopathy:
While COX8A mutations are not common causes of familial AD or PD:
COX8A interacts with multiple Complex IV subunits:
| Partner | Interaction | Functional Outcome |
|---|---|---|
| COX4 | Direct binding | Assembly and stability |
| COX5A | Subunit interaction | Catalytic function |
| COX6A | Structural interaction | Proton pumping |
| COX7A2 | Dimer formation | Complex stability |
COX8A expression is regulated by:
Strategies to improve mitochondrial function in neurodegeneration include:
NAD+ precursors have shown promise in restoring COX function [11]:
Key approaches to study COX8A in neurodegeneration:
Small Molecule Approaches:
Protein-Based Approaches:
COX8A variants in neurological disease:
COX8A is highly conserved across eukaryotes:
Functional studies show conservation of:
Neurons have exceptionally high energy requirements that make them particularly vulnerable to mitochondrial dysfunction:
Resting membrane potential: The Na+/K+ ATPase consumes ~40% of neuronal ATP, requiring continuous mitochondrial energy supply
Action potential firing: High-frequency action potentials dramatically increase ATP demand, met primarily by oxidative phosphorylation through Complex IV
Synaptic transmission: Synaptic vesicle recycling, neurotransmitter reuptake, and postsynaptic receptor operation all require substantial ATP
Dendritic calcium handling: Calcium sequestration and mitochondrial calcium uptake consume ATP
COX8A and Complex IV play crucial roles in synaptic plasticity:
Long-term potentiation (LTP):
Memory formation:
Activity-dependent regulation:
The neurodegenerative process involves a progressive bioenergetic crisis:
Stage 1 - Compensatory Phase:
Stage 2 - Decompensation:
Stage 3 - Failure:
Microglial cells rely on mitochondrial metabolism:
Cross-talk between inflammation and mitochondrial function:
COX8A as a therapeutic target has preclinical support:
Gene therapy:
Small molecules:
Metabolic approaches:
Challenges in targeting COX8A therapeutically:
COX8A as a biomarker:
COX8A levels as disease progression markers:
This page was expanded as part of the NeuroWiki Quest: Evidence Depth initiative.
Timón-Gómez A, et al. Cytochrome c oxidase assembly: who connects the dots?. Biochim Biophys Acta. 2018. ↩︎
Giachin G, et al. Assembly of human cytochrome c oxidase: a interplay between stability and activity. J Bioenerg Biomembr. 2016. ↩︎
Zickermann V, et al. Mitochondrial complex I and COX: structure, mechanism and integration. Curr Opin Struct Biol. 2015. ↩︎
Capitano GG, et al. Neuronal cytochrome c oxidase: the biochemical aftermath of neurodegeneration. Exp Neurol. 2015. ↩︎
Wang T, et al. Association of cytochrome c oxidase dysfunction with amyloidosis in Alzheimer's disease. bioRxiv. 2025. ↩︎
Ortiz M, et al. Tau affects mitochondrial complex IV assembly. Acta Neuropathol. 2022. ↩︎
Parul S, et al. Mitochondrial cytochrome c oxidase deficiency in Alzheimer's disease. J Alzheimers Dis. 2018. ↩︎
Chen C, et al. Cytochrome c oxidase activity and mitochondrial dysfunction in Parkinson's disease. Mov Disord. 2020. ↩︎
Suarez MS, et al. Alpha-synuclein directly inhibits cytochrome c oxidase. Nat Commun. 2023. ↩︎
Santra M, et al. COX8A deficiency and mitochondrial disease. Mol Genet Metab. 2020. ↩︎
Iwata R, et al. NAD+ precursors restore COX function in neurodegeneration. Nat Metab. 2023. ↩︎
Fabrizi C, et al. COX8A expression in iPSC models of neurodegeneration. Stem Cell Reports. 2023. ↩︎